Up­dat­ed: No­var­tis ax­es blood can­cer drug af­ter PhI­II flop, cau­tions on obe­si­ty FO­MO

No­var­tis is wind­ing down a blood can­cer pro­gram hit­ting TIM-3, end­ing the pur­suit of a once-promis­ing im­muno-on­col­o­gy tar­get.

The cut comes as No­var­tis con­sol­i­dates around a lean­er pipeline and R&D strat­e­gy fol­low­ing a glob­al re­struc­tur­ing and the spin­out of gener­ics busi­ness San­doz. The Swiss phar­ma gi­ant not­ed it is now fo­cus­ing on 110 projects in clin­i­cal de­vel­op­ment, com­pared to 115 cit­ed in the last quar­ter­ly up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER